EW
VRTX icon

Elyxium Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Elyxium Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$366K Buy
737
+80
+12% +$35.5K 0.04% 206
2026
Q1 		$293K Buy
657
+89
+16% +$41.5K 0.09% 132
2025
Q4 		$257K Buy
568
+46
+9% +$19.8K 0.07% 155
2025
Q3 		$204K Sell
522
-17
-3% -$7.11K 0.07% 165
2025
Q2 		$240K Buy
539
+103
+24% +$47.5K 0.09% 147
2025
Q1 		$211K Buy
+436
New +$203K 0.09% 148

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Elyxium Wealth's VRTX Position: Q2 2026 in Review

Elyxium Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, buying an estimated $35.5K and bringing the position to 737 shares worth $366K. The position accounts for 0.04% of the portfolio, ranked #206.

Elyxium Wealth first reported a position in VRTX in Q1 2025 and has held it in 6 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Elyxium Wealth held 737 shares of Vertex Pharmaceuticals worth $366K as of Q2 2026.
  • Elyxium Wealth bought 80 Vertex Pharmaceuticals shares in Q2 2026, an estimated $35.5K.
  • Vertex Pharmaceuticals made up 0.04% of Elyxium Wealth's portfolio in Q2 2026, its #206 holding.
  • Elyxium Wealth first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Elyxium Wealth's 13F filing for Q2 2026, filed 3 Aug 2026.